Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Risk & Volatility
Pliant Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
Profitability
This table compares Pliant Therapeutics and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pliant Therapeutics | N/A | -52.17% | -40.46% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Insider & Institutional Ownership
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations for Pliant Therapeutics and Yarrow Bioscience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 246.70%. Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 195.92%. Given Pliant Therapeutics’ higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Yarrow Bioscience.
Valuation & Earnings
This table compares Pliant Therapeutics and Yarrow Bioscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pliant Therapeutics | $1.58 million | 33.91 | -$149.34 million | ($1.49) | -0.58 |
| Yarrow Bioscience | $570,000.00 | 91.81 | -$26.48 million | ($14.64) | -1.34 |
Yarrow Bioscience has lower revenue, but higher earnings than Pliant Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Pliant Therapeutics beats Yarrow Bioscience on 8 of the 13 factors compared between the two stocks.
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
